Rhumatologie

Achievement of a patient acceptable symptom state (PASS) and of a minimum clinically important improvement (MCII) with etanercept in advanced ankylosing spondylitis: results of a double blind, placebo-controlled study (SPINE)

Annals Rheum. Dis. 2010; 69 (3 suppl) (absteact THU0348)

M. Dougados, J. Braun, S. Szanto, B. Combe, M. Elbaz, P. Geher, V. Leblanc and I. Logeart

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France
Rhumatologie

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France

THU0370 CLUSTER-RANDOMIZED PRAGMATIC CLINICAL TRIAL EVALUATING THE POTENTIAL BENEFIT OF A TIGHT-CONTROL AND TREAT-TO-TARGET STRATEGY IN AXIAL SPONDYLOARTHRITIS: THE RESULTS OF THE TICOSPA TRIAL
Rhumatologie

THU0370 CLUSTER-RANDOMIZED PRAGMATIC CLINICAL TRIAL EVALUATING THE POTENTIAL BENEFIT OF A TIGHT-CONTROL AND TREAT-TO-TARGET STRATEGY IN AXIAL SPONDYLOARTHRITIS: THE RESULTS OF THE TICOSPA TRIAL

Treat to target in axial spondyloarthritis: From its concept to its implementation
Rhumatologie

Treat to target in axial spondyloarthritis: From its concept to its implementation